Mosci Camila, Davidzon Guido A, Quon Andrew
Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Drive, Room H-0250, Stanford, CA 94305, USA.
Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Drive, Room H-0250, Stanford, CA 94305, USA.
PET Clin. 2012 Oct;7(4):369-80. doi: 10.1016/j.cpet.2012.06.002. Epub 2012 Aug 20.
Diagnostic imaging plays an important role in the staging, restaging, and treatment monitoring in head and neck cancer (HNC). MR imaging and computed tomography (CT) are the primary imaging modalities for the assessment of this type of tumor; however, they have been proved to be ineffective in some cases. (18)F-2-fluoro-2-deoxy-D-glucose (FDG) PET/CT and more recently PET/MR imaging are increasingly becoming a standard part of the management of HNC. The purpose of this article is to discuss the indications and benefits of (18)F-FDG PET/CT and PET/MR imaging in the management of patients with HNC.
诊断成像在头颈部癌（HNC）的分期、再分期及治疗监测中发挥着重要作用。磁共振成像（MR）和计算机断层扫描（CT）是评估这类肿瘤的主要成像方式；然而，已证实它们在某些情况下效果不佳。氟代脱氧葡萄糖（FDG）PET/CT以及最近的PET/MR成像正日益成为HNC治疗管理的标准组成部分。本文旨在探讨18F-FDG PET/CT和PET/MR成像在HNC患者治疗管理中的适应证及优势。
